Please login to the form below

Not currently logged in
Email:
Password:

PD-L1

This page shows the latest PD-L1 news and features for those working in and with pharma, biotech and healthcare.

Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery

Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery

Patients who are PD-L1 positive represent a subgroup of about 40% of this total.

Latest news

More from news
Approximately 16 fully matching, plus 297 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The presence of PD-L1 expression is often associated with a better response to anti-PD-(L) 1 therapy. ... The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic that is required to prescribe the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    olaparib) plus biologic PD-L1 immunotherapy Imfinzi (durvalumab). ... patients with higher levels of PD-L1 expression in their tumours.

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    We hope to capitalise further on the effects of single agent anti-PD-1/PD-L1 and anti-CTLA-4 monotherapy trials and see even greater survival benefits for patients.”. ... There are a variety of strategies attempting to overcome intrinsic resistance to

  • The good, the bad and the ugly The good, the bad and the ugly

    Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    Hewill oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody currently in aphase 1 clinical trial, recruiting the  expansion

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....